4 charts show why Moderna vaccine recipients may not need boosters as much as people who got Pfizer's vaccine

Emerging patterns suggest Moderna's two-dose vaccine might have a slight edge over Pfizer's in the long run.
24/7 Wall St

Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

Moderna (MRNA) has surged 94% in 2026 so far, crushing Pfizer (PFE) at just +4% and beating Novavax (NVAX) at +41%, as Moderna's leadership restructuring has signaled a 2027-2028 product launch push.
AOL

Pfizer vs Moderna: Which Pharma Stock Has More Upside?

Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) were both leaders in the coronavirus vaccine market. However, as sales of these products have declined significantly in recent years -- due to the ...
24/7 Wall St

Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has ...
Law

Sanofi Opens New Front in mRNA Patent Wars With Suits Against Pfizer, Moderna

The two New Jersey suits assert eight patents against Pfizer and 10 against Moderna, extending existing mRNA litigation beyond delivery technology to manufacturing, purity and non-COVID respiratory ...
AOL

Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

Moderna (NASDAQ:MRNA) stock is jumping again. Shares are up 9% today, trading near $57 in the Tuesday afternoon session. That extends a remarkable 2026 run for the mRNA pioneer. Today's catalyst is ...